Psilocybin’s Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines
Results of research conducted at Emory University, the University of Wisconsin-Madison and UC Berkeley estimate that more than five million Americans suffering from depression could benefit from psilocybin-assisted therapy. This first-of-its-kind peer-reviewed study is scheduled to be published in the scientific journal Psychedelics on September 24, 2024.
How Psilocybin Can Deliver Rapid And Sustained Antidepressant Effects
This latest research report is not the first to look into the use of psilocybin to treat depression. There is a body of research showing that it can potentially deliver quick and continuous antidepressant effects.
For example, results of randomized clinical trials have been published in the Journal of the American Medical Association and by the University of California San Francisco. In fact, psilocybin’s therapeutic properties had been researched as early as the 1950s by Swiss drugmaker Sandoz Group (OTC:SDZNY) as part of specific psychiatric studies.
A Pioneering Drug Development Company Focused On Botanical Therapies
All of this seems to support the work of AJNA BioSciences, based in Littleton, Colorado. The company could be strategically poised to lead and create value in this emerging …